Maralixibat
Records for this ingredient, by country (identity only).
ATC A05AX04 · 9 markets · 27 records
US 6 records · 6 shown of 6
CA 6 records · 6 shown of 6
GB 5 records · 5 shown of 5
- 9.5 mg per mL / per unit basis not statedliquidLivmarli 9.5mg/ml oral solution
- 30 mgtabletLivmarli
- 20 mgtabletLivmarli
- 15 mgtabletLivmarli
- 10 mgtabletLivmarli
ES 1 records · 1 shown of 1
- 9.5 mg/1 mLliquidLivmarli
TW 1 records · 0 shown of 0
1 records · 0 manufacturers 1 registros · 0 fabricantes 1 个记录 · 0 个厂家 1 個記錄 · 0 個廠商
Full list in the data package Lista completa en el paquete de datos 完整清单见数据包 完整清單見資料包
HK 1 records · 0 shown of 0
1 records · 0 manufacturers 1 registros · 0 fabricantes 1 个记录 · 0 个厂家 1 個記錄 · 0 個廠商
Full list in the data package Lista completa en el paquete de datos 完整清单见数据包 完整清單見資料包
JP 1 records · 1 shown of 1
- 1 %/30 mLotherリブマーリ内用液10mg/mL
EU 1 records · 0 shown of 0
EU centralised authorisation (EMA) — Authorised at EU level — not a record of sale in any single country. The EU register carries no strength, dosage form or pack size.
1 records · 0 manufacturers 1 registros · 0 fabricantes 1 个记录 · 0 个厂家 1 個記錄 · 0 個廠商
Full list in the data package Lista completa en el paquete de datos 完整清单见数据包 完整清單見資料包
FR 1 records · 1 shown of 1
- 9.5 mg per mL / per unit basis not statedliquidLIVMARLI 9,5 mg/mL, solution buvable
Some strengths are recorded without a per mL / per unit basis. They are shown as recorded and are not compared with other markets.
| Strength / form / release | US | GB | CA | ES | TW | HK | JP | EU | FR |
|---|---|---|---|---|---|---|---|---|---|
| 9.5 mg per mL / per unit basis not stated cannot compare liquid | Livmarli | Livmarli 9.5mg/ml oral solution | Livmarli | LIVMARLI 9,5 mg/mL, solution buvable | |||||
| 30 mg tablet | Livmarli | Livmarli | Livmarli | ||||||
| 20 mg tablet | Livmarli | Livmarli | Livmarli | ||||||
| 15 mg tablet | Livmarli | Livmarli | Livmarli | ||||||
| 10 mg tablet | Livmarli | Livmarli | Livmarli | ||||||
| 19 mg per mL / per unit basis not stated cannot compare liquid | Livmarli | Livmarli | |||||||
| 9.5 mg/1 mL liquid | Livmarli | ||||||||
| 1 %/30 mL other | リブマーリ内用液10mg/mL | ||||||||
liquid | Livmarli 邁芮倍口服溶液 | ||||||||
unknown | Livmarli 9.5mg/ml oral solution | Livmarli |
Scroll horizontally for more markets →
Each country column shows the locally registered trade names — not translations.
4 more strength/form rows are recorded only in ES · TW · HK · JP · EU and are not shown in this table. Hay 4 filas de concentración/forma registradas solo en ES · TW · HK · JP · EU que no se muestran en esta tabla. 另有 4 个规格/剂型仅在 ES · TW · HK · JP · EU 有记录（未在本表显示）。 另有 4 個規格/劑型僅在 ES · TW · HK · JP · EU 有記錄（未在本表顯示）。
“not disclosed” means the source does not publish the strength — it does not mean the product has none.
Hong Kong records are name/ingredient-level only: no strength, dosage form or registration status; on the register does not prove current supply.
EU centralised authorisation (EMA) — Authorised at EU level — not a record of sale in any single country. The EU register carries no strength, dosage form or pack size.
Discontinued, withdrawn or unverified-status products are hidden by default; Hong Kong and Australia records are shown as exceptions.